CTLA-4 gene variant -1661A>G may predict the onset of endocrine adverse events in metastatic melanoma patients treated with ipilimumab

Italian Melanoma Intergroup (IMI)

Research output: Contribution to journal › Letter

3 Citations (Scopus)
Original languageEnglish
Pages (from-to)59-61
Number of pages3
JournalEuropean Journal of Cancer
Volume97
DOIs
Publication statusPublished - Jul 1 2018

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

CTLA-4 gene variant -1661A>G may predict the onset of endocrine adverse events in metastatic melanoma patients treated with ipilimumab. / Italian Melanoma Intergroup (IMI).

In: European Journal of Cancer, Vol. 97, 01.07.2018, p. 59-61.

Research output: Contribution to journal › Letter

Italian Melanoma Intergroup (IMI) 2018, 'CTLA-4 gene variant -1661A>G may predict the onset of endocrine adverse events in metastatic melanoma patients treated with ipilimumab', European Journal of Cancer, vol. 97, pp. 59-61. https://doi.org/10.1016/j.ejca.2018.04.005
Italian Melanoma Intergroup (IMI). CTLA-4 gene variant -1661A>G may predict the onset of endocrine adverse events in metastatic melanoma patients treated with ipilimumab. European Journal of Cancer. 2018 Jul 1;97:59-61. https://doi.org/10.1016/j.ejca.2018.04.005
Italian Melanoma Intergroup (IMI). / CTLA-4 gene variant -1661A>G may predict the onset of endocrine adverse events in metastatic melanoma patients treated with ipilimumab. In: European Journal of Cancer. 2018 ; Vol. 97. pp. 59-61.
@article{3ca3b525ebde4abdaee48451044e23cd,
title = "CTLA-4 gene variant -1661A>G may predict the onset of endocrine adverse events in metastatic melanoma patients treated with ipilimumab",
author = "{Italian Melanoma Intergroup (IMI)} and Paola Queirolo and Beatrice Dozin and Anna Morabito and Barbara Banelli and Roberta Carosio and Vincenzo Fontana and Ferrucci, {Pier Francesco} and Chiara Martinoli and Emilia Cocorocchio and Ascierto, {Paolo A.} and Gabriele Madonna and Ester Simeone and {De Galitiis}, Federica and {Antonini Cappellini}, {Gian Carlo} and Paolo Marchetti and Michele Guida and Stefania Tommasi and Laura Ghilardi and Barbara Merelli and Paolo Fava and Simona Osella-Abate and Massimo Guidoboni and Massimo Romani and Diego Ferone and Francesco Spagnolo and Pistillo, {Maria Pia}",
year = "2018",
month = "7",
day = "1",
doi = "10.1016/j.ejca.2018.04.005",
language = "English",
volume = "97",
pages = "59--61",
journal = "European Journal of Cancer",
issn = "0959-8049",
publisher = "Elsevier Ltd",

}

TY - JOUR

T1 - CTLA-4 gene variant -1661A>G may predict the onset of endocrine adverse events in metastatic melanoma patients treated with ipilimumab

AU - Italian Melanoma Intergroup (IMI)

AU - Queirolo, Paola

AU - Dozin, Beatrice

AU - Morabito, Anna

AU - Banelli, Barbara

AU - Carosio, Roberta

AU - Fontana, Vincenzo

AU - Ferrucci, Pier Francesco

AU - Martinoli, Chiara

AU - Cocorocchio, Emilia

AU - Ascierto, Paolo A.

AU - Madonna, Gabriele

AU - Simeone, Ester

AU - De Galitiis, Federica

AU - Antonini Cappellini, Gian Carlo

AU - Marchetti, Paolo

AU - Guida, Michele

AU - Tommasi, Stefania

AU - Ghilardi, Laura

AU - Merelli, Barbara

AU - Fava, Paolo

AU - Osella-Abate, Simona

AU - Guidoboni, Massimo

AU - Romani, Massimo

AU - Ferone, Diego

AU - Spagnolo, Francesco

AU - Pistillo, Maria Pia

PY - 2018/7/1

Y1 - 2018/7/1

UR - http://www.scopus.com/inward/record.url?scp=85047747670&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85047747670&partnerID=8YFLogxK

U2 - 10.1016/j.ejca.2018.04.005

DO - 10.1016/j.ejca.2018.04.005

M3 - Letter

AN - SCOPUS:85047747670

VL - 97

SP - 59

EP - 61

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

ER -

Access to Document

Related content

Projects

Ospedale Policlinico San Martino - PERSONALIZZAZIONE DELLE STRATEGIE TERAPEUTICHE IN ONCOLOGIA

Project: Other project